Treatment of chronic hepatitis B patients with interferon α1b and lamivudive

Objective To evaluate the short term therapeutic effect of interferon α1b and lamivudive on the treatment of chronic hepatitis B.Methods Seventeen patients with chronic hepatitis B whose HBeAg and HBV DNA were positive received combined treatment with interferon α1b and lamivudive for 6 months and were compared to 21 cases only with interferon α1b treatment.The changes of ALT,HBV DNA,HBeAg and the side effects of the two groups were observed.Results ALT normalization rate in the combined therapy group was 88.2% after six months of treatment and HBeAg negative rate was 64.7%.In the other group ALT normalization rate and HBeAg negative rate were 85.7% and 57.1% respectively.There is no statistically significant difference between the two groups.HBV DNA negative rate in the combined therapy group was 88.2% and 57.1% in the other group.HBV DNA negative rate in the combined therapy group was significantly higher than that in the other group(P0.05).Conclusion Combined interferon α1b with lamivudive is safe and effective in the treatment of chronic hepatitis B.